Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma.

Jin MC, Wu A, Xiang M, Azad TD, Soltys SG, Li G, Pollom EL.

World Neurosurg. 2019 Apr 19. pii: S1878-8750(19)31097-6. doi: 10.1016/j.wneu.2019.04.103. [Epub ahead of print]

PMID:
31009783
2.

Treatment and survival of patients harboring histological variants of glioblastoma.

Ortega A, Nuño M, Walia S, Mukherjee D, Black KL, Patil CG.

J Clin Neurosci. 2014 Oct;21(10):1709-13. doi: 10.1016/j.jocn.2014.05.003. Epub 2014 Jun 26.

PMID:
24980627
3.

Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations.

Martinez R, Roggendorf W, Baretton G, Klein R, Toedt G, Lichter P, Schackert G, Joos S.

Cancer Genet Cytogenet. 2007 May;175(1):26-34.

PMID:
17498554
4.

Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas.

Shi ZF, Li KK, Kwan JSH, Yang RR, Aibaidula A, Tang Q, Bao Y, Mao Y, Chen H, Ng HK.

Brain Pathol. 2019 Mar 12. doi: 10.1111/bpa.12720. [Epub ahead of print]

PMID:
30861589
5.

Primary glioblastoma multiforme in younger patients: a single-institution experience.

Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M.

Tumori. 2006 Sep-Oct;92(5):407-11.

PMID:
17168433
6.

Variation in management of spinal gliobastoma multiforme: results from a national cancer registry.

Moinuddin FM, Alvi MA, Kerezoudis P, Wahood W, Meyer J, Lachance DH, Bydon M.

J Neurooncol. 2019 Jan;141(2):441-447. doi: 10.1007/s11060-018-03054-2. Epub 2018 Nov 20.

PMID:
30460627
7.

Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.

Kozak KR, Moody JS.

Neuro Oncol. 2009 Dec;11(6):833-41. doi: 10.1215/15228517-2008-123.

8.

Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.

Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD.

JAMA Neurol. 2016 Jul 1;73(7):821-8. doi: 10.1001/jamaneurol.2016.0839.

PMID:
27214765
9.

Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.

Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G.

J Neurosurg. 2018 Apr;128(4):1133-1138. doi: 10.3171/2016.12.JNS162291. Epub 2017 Jun 16.

PMID:
28621623
10.

Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database.

Zhu P, Du XL, Zhu JJ, Esquenazi Y.

J Neurosurg. 2019 Feb 15:1-12. doi: 10.3171/2018.10.JNS182247. [Epub ahead of print]

PMID:
30771780
11.

A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord.

Konar SK, Bir SC, Maiti TK, Nanda A.

J Neurosurg Pediatr. 2017 Feb;19(2):239-248. doi: 10.3171/2016.8.PEDS1631. Epub 2016 Nov 4. Review.

PMID:
27813458
12.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
13.

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A.

PLoS One. 2016 Jun 2;11(6):e0156422. doi: 10.1371/journal.pone.0156422. eCollection 2016.

14.

Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.

Back MF, Ang EL, Ng WH, See SJ, Lim CC, Chan SP, Yeo TT.

Ann Acad Med Singapore. 2007 May;36(5):338-42.

15.

Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.

Oh T, Rutkowski MJ, Safaee M, Sun MZ, Sayegh ET, Bloch O, Tihan T, Parsa AT.

J Clin Neurosci. 2014 Dec;21(12):2129-34. doi: 10.1016/j.jocn.2014.04.011. Epub 2014 Jul 16.

PMID:
25037316
16.

Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population.

Haque W, Verma V, Butler EB, Teh BS.

Am J Clin Oncol. 2018 Feb;41(2):167-172. doi: 10.1097/COC.0000000000000417.

PMID:
29369825
17.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
18.

Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival.

Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG.

J Radiat Res. 2018 Mar 1;59(suppl_1):i11-i18. doi: 10.1093/jrr/rrx103.

19.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
20.

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.

Matsuda M, Yamamoto T, Ishikawa E, Nakai K, Zaboronok A, Takano S, Matsumura A.

Br J Radiol. 2011 Dec;84 Spec No 1:S54-60. doi: 10.1259/bjr/29022270. Epub 2011 Mar 22.

Supplemental Content

Support Center